Investments in artificial intelligence (AI) for drug discovery are surging. Big Pharmas are throwing big bucks at AI. Sanofi signed a 300 Million dollars deal with the Scottish AI startup Exscentia, and GSK did the same for 42 Million dollars. Also, the Silicon Valley VC firm Andreessen Horowitz launched a new 450 Million dollars bio investment fund, with one focus area in applications of AI to drug discovery.
In this craze, lots of pharma and biotech decision-makers wonder whether they should jump on the bandwagon, or wait and see.
This content available exclusively for BPT Mebmers
Topics: Emerging Technologies